Target intelligence / Profile preview

G protein subunit beta 3 (GNB3)

Target
GNB3
Molecular classification
G protein beta subunit, Signal transduction molecule, WD repeat-containing protein, Heterotrimeric G protein subunit
01

Overview

G protein subunit beta 3 (GNB3) is a regulatory subunit of heterotrimeric G proteins, which are involved in transducing signals from membrane receptors to intracellular effectors in cells. The beta subunit, along with gamma and alpha subunits, is essential for modulating G protein-coupled receptor (GPCR) signaling, GDP/GTP exchange, and interaction with downstream effectors. GNB3 has been widely studied for its C825T polymorphism, which is associated with essential hypertension, obesity, and several signal transduction phenotypes. The gene belongs to the WD-repeat G protein beta family and is expressed in various tissues, where it helps couple extracellular signals to cellular responses. The C825T variant produces a splice variant (GNB3-s), leading to altered signaling capacity that is implicated in disease risk, especially hypertension. No drugs currently directly target GNB3, but its influence on signal transduction may modulate therapeutic responses to molecules acting via GPCRs.

Other names
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3Transducin beta chain 3G protein, beta-3 subunitGTP-binding regulatory protein beta-3 chainguanine nucleotide-binding protein (G protein), beta polypeptide 3GNB3-sCSNB1HHG2Dheterotrimeric guanine nucleotide-binding protein 2DG protein subunit β 3Gβ3
02

Mechanism of action

Not directly targeted; GNB3 variants may influence signal transduction response and drug efficacy, especially for agents acting via G protein-coupled receptors.

03

Biological functions

Signal transductionModulation of receptor-effector couplingRegulation of GTPase activityMaintenance of G protein-effector interaction
04

Disease associations

Cardiovascular disease (notably hypertension)ObesityCongenital stationary night blindness (type 1H)Schizophrenia (response to antipsychotics)
05

Safety considerations

No notable off-target or direct safety risks identified from specific GNB3-targeted drugs; genetic polymorphisms may affect disease susceptibility or therapeutic efficacy rather than direct toxicity
06

Interacting drugs

No approved or investigational drugs are currently known to directly target GNB3; its variants may modulate response to some drugs (e.g., antipsychotics)
07

Biomarkers

C825T (rs5443) polymorphism for hypertension riskpossibly modulator for metabolic phenotypes (triglycerides, glucose, uric acid levels in hypertension)

Beyond the preview

Go deeper on G protein subunit beta 3 (GNB3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G protein subunit beta 3 (GNB3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call